Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Dec. 31, 2015 | Feb. 10, 2016 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Dec. 31, 2015 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | QTNT | |
Entity Registrant Name | Quotient Ltd | |
Entity Central Index Key | 1,596,946 | |
Current Fiscal Year End Date | --03-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 25,408,950 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Current assets: | ||
Cash and cash equivalents | $ 24,061 | $ 37,525 |
Trade accounts receivable, net | 1,479 | 1,808 |
Inventories | 7,812 | 4,608 |
Prepaid expenses and other current assets | 6,305 | 5,580 |
Total current assets | 39,657 | 49,521 |
Property and equipment, net | 48,944 | 29,733 |
Intangible assets, net | 952 | 950 |
Total assets | 89,553 | 80,204 |
Current liabilities: | ||
Accounts payable | 9,241 | 7,238 |
Accrued compensation and benefits | 1,777 | 2,565 |
Accrued expenses and other current liabilities | 3,992 | 8,787 |
Financial liability in respect of share warrants | 31,011 | |
Current portion of long-term debt | 4,500 | |
Current portion of lease incentive | 426 | 435 |
Current portion of capital lease obligation | 168 | 239 |
Total current liabilities | 15,604 | 54,775 |
Long-term debt, less current portion | 28,689 | 9,853 |
Lease incentive, less current portion | 1,383 | 1,740 |
Capital lease obligation, less current portion | 1,794 | 276 |
Total liabilities | $ 63,433 | $ 81,819 |
Commitments and contingencies | ||
Shareholders' equity (deficit) | ||
Additional paid in (distribution in excess of) capital | $ 11,040 | $ (6,684) |
Accumulated other comprehensive loss | (5,279) | (5,102) |
Accumulated deficit | (98,719) | (74,354) |
Total shareholders' equity (deficit) | 26,120 | (1,615) |
Total liabilities and shareholders' equity (deficit) | 89,553 | 80,204 |
7% Cumulative Redeemable Preference Shares [Member] | ||
Current liabilities: | ||
Preferred stock value | 15,963 | 15,175 |
Ordinary Shares [Member] | ||
Shareholders' equity (deficit) | ||
Common stock value | $ 119,078 | $ 84,525 |
CONDENSED CONSOLIDATED BALANCE3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | 9 Months Ended | |
Dec. 31, 2015 | Mar. 31, 2015 | |
Common stock, par value | ||
Common stock, shares issued | 20,964,405 | 17,020,574 |
Common stock, shares outstanding | 17,020,574 | |
7% Cumulative Redeemable Preference Shares [Member] | ||
Dividend percentage | 7.00% | |
Ordinary Shares [Member] | ||
Common stock, par value | ||
Common stock, shares issued | 20,964,405 | 17,020,574 |
Common stock, shares outstanding | 20,964,405 | 17,020,574 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenue: | ||||
Product sales | $ 4,354 | $ 3,962 | $ 13,477 | $ 13,756 |
Other revenues | 100 | 750 | ||
Total revenue | 4,354 | 4,062 | 13,477 | 14,506 |
Cost of revenue | (2,225) | (2,204) | (7,100) | (7,361) |
Gross profit | 2,129 | 1,858 | 6,377 | 7,145 |
Operating expenses: | ||||
Sales and marketing | (918) | (789) | (2,350) | (2,095) |
Research and development, net of government grants | (6,931) | (4,453) | (22,122) | (13,573) |
General and administrative expense: | ||||
Compensation expense in respect of share options and management equity incentives | (566) | (305) | (1,380) | (814) |
Other general and administrative expenses | (6,493) | (3,638) | (16,768) | (10,617) |
Total general and administrative expense | (7,059) | (3,943) | (18,148) | (11,431) |
Total operating expense | (14,908) | (9,185) | (42,620) | (27,099) |
Operating loss | (12,779) | (7,327) | (36,243) | (19,954) |
Other income (expense): | ||||
Interest expense, net | (1,134) | (541) | (2,992) | (1,613) |
Change in financial liability for share warrants | 3,830 | (34,565) | 15,857 | (33,581) |
Other, net | 305 | 130 | (987) | (1,490) |
Other income (expense), net | 3,001 | (34,976) | 11,878 | (36,684) |
Loss before income taxes | (9,778) | (42,303) | (24,365) | (56,638) |
Net loss | (9,778) | (42,303) | (24,365) | (56,638) |
Other comprehensive income (loss): | ||||
Change in fair value of effective portion of foreign currency cash flow hedges | (89) | (35) | 120 | (288) |
Foreign currency loss | (1,491) | (1,219) | (297) | (2,711) |
Other comprehensive loss, net | (1,580) | (1,254) | (177) | (2,999) |
Comprehensive loss | (11,358) | (43,557) | (24,542) | (59,637) |
Net loss available to ordinary shareholders - basic and diluted | $ (9,778) | $ (42,303) | $ (24,365) | $ (56,638) |
Loss per share - basic and diluted | $ (0.48) | $ (2.80) | $ (1.33) | $ (3.95) |
Weighted-average shares outstanding - basic and diluted | 20,398,132 | 15,101,441 | 18,284,708 | 14,352,476 |
CONDENSED CONSOLIDATED STATEME5
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - 9 months ended Dec. 31, 2015 - USD ($) $ in Thousands | Total | Ordinary Shares [Member] | Additional Paid in (Distribution in Excess of) Capital [Member] | Accumulated Other Comprehensive Loss [Member] | Accumulated Deficit [Member] |
Beginning balance at Mar. 31, 2015 | $ (1,615) | $ 84,525 | $ (6,684) | $ (5,102) | $ (74,354) |
Beginning balance, Shares at Mar. 31, 2015 | 17,020,574 | 17,020,574 | |||
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount | $ 40 | $ 40 | |||
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares | 21,112 | ||||
Issue of shares upon exercise of warrants, Amount | 49,667 | $ 34,513 | 15,154 | ||
Issue of shares upon exercise of warrants, Shares | 3,922,719 | ||||
Issue of warrants | 1,190 | 1,190 | |||
Net loss | (24,365) | (24,365) | |||
Change in the fair value of the effective portion of foreign currency cash flow hedges | 120 | 120 | |||
Foreign currency translation loss | (297) | (297) | |||
Other comprehensive loss | (177) | (177) | |||
Stock-based compensation | 1,380 | 1,380 | |||
Ending balance at Dec. 31, 2015 | $ 26,120 | $ 119,078 | $ 11,040 | $ (5,279) | $ (98,719) |
Ending balance, Shares at Dec. 31, 2015 | 20,964,405 |
CONDENSED CONSOLIDATED STATEME6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
OPERATING ACTIVITIES: | ||
Net loss | $ (24,365) | $ (56,638) |
Adjustments to reconcile net loss to net cash provided by operating activities: | ||
Depreciation and amortization | 1,573 | 938 |
Share-based compensation | 1,380 | 814 |
Amortization of lease incentive | (327) | (345) |
Amortization of deferred debt issue costs | 1,250 | 587 |
Accrued preference share dividends | 788 | |
Change in financial liability for share warrants | (15,857) | 33,581 |
Net change in assets and liabilities: | ||
Trade accounts receivable, net | 307 | 161 |
Inventories | (3,249) | (365) |
Accounts payable and accrued liabilities | (2,675) | 4,109 |
Accrued compensation and benefits | (803) | (320) |
Other assets | (725) | (731) |
Net cash used in operating activities | (42,703) | (18,209) |
INVESTING ACTIVITIES: | ||
Purchase of property and equipment | (19,832) | (13,429) |
Purchase of intangible assets | (64) | (203) |
Net cash used in investing activities | (19,896) | (13,632) |
FINANCING ACTIVITIES: | ||
Proceeds from finance leases | 55 | 304 |
Proceeds from drawdown of new debt, net of costs | 14,297 | |
Proceeds from issuance of ordinary shares | 34,553 | 59,329 |
Net cash generated from financing activities | 48,905 | 59,633 |
Effect of exchange rate fluctuations on cash and cash equivalents | 230 | (1,934) |
Change in cash and cash equivalents | (13,464) | 25,858 |
Beginning cash and cash equivalents | 37,525 | 7,192 |
Ending cash and cash equivalents | 24,061 | 33,050 |
Supplemental cash flow disclosures: | ||
Interest paid | $ 1,463 | $ 346 |
Description of Business and Bas
Description of Business and Basis of Presentation | 9 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Description of Business and Basis of Presentation | Note 1. Description of Business and Basis of Presentation Description of Business The principal activity of Quotient Limited (the “Company”) and its subsidiaries (the “Group”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide. Basis of Presentation The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and are unaudited. In accordance with those rules and regulations, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) considered necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. The March 31, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The financial statements should be read in conjunction with the audited consolidated financial statements at and for the year ended March 31, 2015 included in the Company’s Annual Report on Form 10-K for the year then ended. The results of operations for the nine month period ended December 31, 2015 are not necessarily indicative of the results of operations that may be expected for the year ending March 31, 2016 and any future period. The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $98.7 million as of December 31, 2015. At December 31, 2015 the Company had cash holdings of $24.1 million and had covenants in place with lenders to maintain cash holdings above $10 million. As explained in Note 10, on February 10, 2016 the Company completed a public equity offering to raise $36.9 million, net of underwriting fees and commissions and other offering expenses. substantial doubt about its ability to continue as a going concern. The |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of December, 2015 and March 31, 2015, all cash and cash equivalents comprised readily accessible cash balances except for $307 at December 31, 2015 and $314 at March 31, 2015 held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary. Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting entirely of foreign exchange contracts, are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing. The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of December 31, 2015 and at March 31, 2015. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of December 31, 2015 and March 31, 2015. This customer represented 37% and 47% of the accounts receivable balances as of December 31, 2015 and March 31, 2015, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the nine month periods ended December 31, 2015 and December 31, 2014. This customer represented 56% of total product sales for the nine month period ended December 31, 2015 and 55% for the nine month period ended December 31, 2014. Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: · Level 1—Quoted prices in active markets for identical assets or liabilities. · Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. · Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 6, “Commitment and Contingencies,” for information and related disclosures regarding the Company’s fair value measurements. Inventory Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of December 31, 2015 and March 31, 2015. Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: · Land—not depreciated. · Plant, machinery and equipment—4 to 25 years; · Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Intangible Assets and Goodwill Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles assets—7 years The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the nine month periods ended December 31, 2015 or December 31, 2014. Revenue Recognition The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. In June 2013, the Company entered into an agreement with Ortho-Clinical Diagnostics Inc. (“OCD”) to develop a range of rare antisera products. The Company had been working on this project for more than a year before the formal agreement was signed with OCD. Under the terms of the agreement, the Company is entitled to receive milestone payments of $1,400 upon the receipt of FDA approval of the rare antisera products and two further milestones of $500 each upon the updating of the CE-mark and FDA approvals to cover use of the products on OCD’s automation platform. The Company has concluded that as each of these milestones require significant levels of development work to be undertaken and there was no certainty at the start of the project that the development work would be successful, these milestones are substantive and will be accounted for under the milestone method of revenue recognition. The agreement also contains one further milestone of $650 payable upon fulfillment of $250 of cumulative orders of the rare antisera products covered by the agreement. This payment represents a royalty payment and was recognized in the quarter ended June 30, 2014 when the sales target was achieved. Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants or tax credits are available, the income concerned is included as a credit against the related expense. Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s Condensed Consolidated Statements of Comprehensive Loss. Compensation cost related to restricted stock units with a market condition is recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided. Stock-based compensation cost for restricted stock units granted to non-employees is measured when the awards vest and the expense is recognized during the period the related services are rendered. In determining the fair value of the stock-based compensation payments in respect of share options, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures). The Company uses a barrier option pricing model to determine the grant date fair value of its multi-year performance related restricted stock unit awards. This requires the use of similar assumptions to the Black-Scholes model. Debt Issuance Costs On September 30, 2015, the Company elected to adopt early the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. In view of the refinancing of the Company’s secured credit facility on August 3, 2015 (see note 4), the Company believes that it is preferable to adopt this presentation in the year of refinancing in order to reflect more accurately the assets of the Company and the substance of the financing arrangements. Comparative financial statements of prior years have been adjusted to apply the new presentation retrospectively. This had the effect of reducing “Prepaid expenses and other current assets” and “Other non-current assets at March 31, 2015 by $549 and $366, respectively, with a consequential reduction in “Long term debt, less current portion” of $915. There has been no impact on the comparative Statements of comprehensive loss, Statement of changes in shareholders’ deficit or Statements of cash flows. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Dec. 31, 2015 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 3. Intangible Assets December 31, 2015 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Ave. Remaining Useful Customer relationships $ 2,915 $ (2,915 ) $ — — Brands associated with acquired cell lines 601 (125 ) 476 31.7 years Product licenses 770 (294 ) 476 6.2 years Other intangibles 189 (189 ) — — Total $ 4,475 $ (3,523 ) $ 952 March 31, 2015 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Ave. Remaining Useful Customer relationships $ 2,923 $ (2,923 ) $ — — Brands associated with acquired cell lines 603 (115 ) 488 32.4 years Product licenses 703 (241 ) 462 6.6 years Other intangibles 190 (190 ) — — Total $ 4,419 $ (3,469 ) $ 950 |
Debt
Debt | 9 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Debt | Note 4. Debt Long-term debt comprises: December 31, 2015 March 31, 2015 Total debt $ 30,000 $ 15,000 Less current portion — (4,500 ) Long-term debt $ 30,000 $ 10,500 Deferred debt costs, net of amortization (299 ) (428 ) Fair value of associated share warrant, net of amortization (1,012 ) (219 ) $ 28,689 $ 9,853 On August 3, 2015, the Company drew down $30,000 under a new secured credit facility agreement with MidCap Financial Trust. The facility is repayable over a four year period with no repayments until March 1, 2017 when the first of 30 equal monthly repayments is due. If the Company achieves CE Mark approvals for the MosaiQ TM At December 31, 2015, the outstanding debt is repayable as follows: Within 1 year $ — Between 1 and 2 years 10,000 Between 2 and 3 years 12,000 Between 3 and 4 years 8,000 Total debt $ 30,000 |
Consolidated Balance Sheet Deta
Consolidated Balance Sheet Detail | 9 Months Ended |
Dec. 31, 2015 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Consolidated Balance Sheet Detail | Note 5. Consolidated Balance Sheet Detail Inventory The following table summarizes inventory by category for the dates presented: December 31, 2015 March 31, 2015 Raw materials $ 4,137 $ 1,180 Work in progress 2,532 2,071 Finished goods 1,143 1,357 Total inventories $ 7,812 $ 4,608 Property and equipment The following table summarizes property and equipment by categories for the dates presented: December 31, 2015 March 31, 2015 Land $ 1,525 $ — Plant and Machinery 35,886 21,688 Leasehold improvements 16,350 11,412 Total property and equipment 53,761 33,100 Less: accumulated depreciation (4,817 ) (3,367 ) Total property and equipment, net $ 48,944 $ 29,733 Depreciation expenses were $643 and $316 in the quarters ended December 31, 2015 and December 31, 2014 respectively and $1,510 and $873 in the nine month periods ended December 31, 2015 and December 31, 2014 respectively. Accrued compensation and benefits Accrued compensation and benefits consist of the following: December 31, 2015 March 31, 2015 Salary and related benefits $ 59 $ 300 Accrued vacation 267 165 Accrued payroll taxes 551 302 Accrued incentive payments 900 1,798 Total accrued compensation and benefits $ 1,777 $ 2,565 Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: December 31, 2015 March 31, 2015 Accrued legal and professional fees $ 182 $ 3,758 Accrued interest 225 112 Goods received not invoiced 933 787 Accrued capital expenditure 230 972 Accrued development expenditure 1,786 2,110 Other accrued expenses 636 1,048 Total accrued expenses and other current liabilities $ 3,992 $ 8,787 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Dec. 31, 2015 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 6. Commitments and Contingencies Government Grant In 2008, the Company was awarded research and development grant funding from Scottish Enterprise amounting to £1,791, for the development of MosaiQ TM Hedging arrangements The Company’s subsidiary in the United Kingdom (“UK”) has entered into twelve forward exchange contracts to sell $500 and purchase pounds sterling at £1:$1.50 in each calendar month through December 2016 as a hedge of its U.S. dollar denominated revenues. The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations. Share warrants As part of its initial public offering in April 2014 the Company issued 5 million warrants each to acquire 0.8 of an ordinary share for a price of $8.80 per whole share (“IPO warrants”). During the period from the initial public offering to October 26, 2015 when the warrants expired, 4,981,052 of these warrants were exercised and the remaining 18,948 expired on October 26, 2015. As of March 31, 2015, the financial statements included a financial liability of $31,011 in respect of these warrants which was equal to the market price of the outstanding warrants at that date. As of December 31, 2015 no financial liability in respect of the IPO warrants was included in the financial statements. The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Foreign currency forward contracts $ — $ — $ — $ — Total assets measured at fair value $ — $ — $ — $ — December 31, 2015 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts $ — $ 79 $ — $ 79 Fair value of share warrants — — — — Total liabilities measured at fair value $ — $ 79 $ — $ 79 March 31, 2015 Level 1 Level 2 Level 3 Total Assets: Foreign currency forward contracts $ — $ — $ — $ — Total assets measured at fair value $ — $ — $ — $ — March 31, 2015 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts $ 199 $ — $ — $ 199 Fair value of share warrants 31,011 — — 31,011 Total liabilities measured at fair value $ 31,210 $ — $ — $ 31,210 The change in the estimated fair value of share warrant liabilities is summarized below: March 31,2015 $ 31,011 Change in fair value of ordinary share warrants (15,857 ) Exercise and expiry of warrants (15,154 ) December 31, 2015 $ — |
Ordinary Shares
Ordinary Shares | 9 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Ordinary Shares | Note 7. Ordinary Shares Ordinary Shares The Company’s issued and outstanding ordinary shares were as follows: Shares Issued and Outstanding December 31, 2015 March 31, 2015 Par value Ordinary shares 20,964,405 17,020,574 $ — Total 20,964,405 17,020,574 $ — Preference shares The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share December 31, 2015 March 31, 2015 December 31, 2015 March 31, 2015 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 23.94 $ 22.76 Total 666,665 666,665 |
Share-Based Compensation
Share-Based Compensation | 9 Months Ended |
Dec. 31, 2015 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Share-Based Compensation | Note 8. Share-Based Compensation The Company records share-based compensation expense in respect of options, multi-year performance based restricted stock units (“MRSUs”) and restricted stock units (“RSUs”) issued under its share incentive plans. Share-based compensation expense amounted to $1,380 and $814 in the nine month periods ended December 31, 2015 and December 31, 2014, respectively. Share option activity The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2015 1,208,118 $ 5.58 103 Granted 396,427 14.86 120 Exercised (8,612 ) 4.66 — Forfeited (6,695 ) 12.08 — Outstanding — December 31, 2015 1,589,238 $ 7.87 99 Exercisable —December 31, 2015 634,466 $ 4.13 91 The closing price of the Company’s Ordinary Shares on The NASDAQ Global Market on December 31, 2015 was $16.00. The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 20, 2015 312,300 $ 15.17 $ 15.17 $ 6.08 August 5, 2015 8,000 $ 16.70 $ 16.70 $ 6.54 September 2, 2015 25,000 $ 16.34 $ 16.34 $ 6.52 October 31, 2015 39,727 $ 11.62 $ 11.62 $ 4.76 November 4, 2015 11,400 $ 13.00 $ 13.00 $ 5.33 Determining the fair value of share incentive awards The fair value of each share incentive grant was determined by the Company using the Black-Scholes options pricing model. Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected volatility . The expected volatility was based on the historical share volatilities of a number of the Company’s publicly listed peers over a period equal to the expected terms of the options as the Company did not have a sufficient trading history to use the volatility of its own ordinary shares. Fair value of ordinary shares. The fair value of the ordinary shares is based upon the closing price of the Company’s shares on The NASDAQ Global Market on the last trading day prior to the date of grant. Risk-Free Interest Rate. The risk-free interest rate is based on the US Treasury 10-year bond yield in effect at the time of grant. Expected term. The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards. Expected dividend. According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price. A summary of the assumptions applicable to the share options issued in the current financial year is as follows: May 20, 2015 August 5, 2015 September 2, 2015 October 31, 2015 November 4, 2015 Risk-free interest rate 2.29 % 2.27 % 2.18 % 2.14 % 2.23 % Expected lives (years) 3 3 3 3 3 Volatility 57.14 % 55.67 % 57.01 % 58.86 % 58.86 % Dividend yield — — — — — Grant date fair value (per share) $ 15.17 $ 16.70 $ 16.34 $ 11.62 $ 13.00 Number granted 312,300 8,000 25,000 39,727 11,400 The Company awarded 137,000 MRSUs on May 20, 2015. These MRSUs will vest if the volume weighted average price of the Company’s ordinary shares exceeds $60 for a continuous twenty day period between April 1, 2018 and December 31, 2018. The Company determined the grant date fair value of the MRSUs using a barrier option pricing model with the same grant date fair value per share, risk free interest rate, volatility and dividend yield assumptions as the options awarded on the same date. This resulted in a grant date fair value of $6.09 per MRSU on May 20, 2015. On September 2, 2015 the Company issued 25,000 RSUs which will vest if specific sales performance targets are met prior to December 31, 2022. The Company expects these performance targets to be met and share based compensation expense is being recognized on these awards over the period to the date when the sales performance targets are expected to be achieved. The Company also issued 10,000 RSUs on May 20, 2015, 9,867 RSUs on September 4, 2015 and 10,328 RSUs on October 31, 2015 which vest over a two year period from the date of grant. On November 4, 2015 the Company issued 8,000 RSUs which vest over a three year period from the date of grant. During the quarter ended September 30, 2014, the Company awarded 50,000 RSUs to a non-executive director upon his appointment as a director of the Company. These vest in equal annual installments over the four year period following the date of grant. During the nine months ended December 31, 2015, 12,500 of these RSUs vested resulting in the issuance of 12,500 ordinary shares and at December 31, 2015, 37,500 of these RSUs remained outstanding. |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Dec. 31, 2015 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | Note 9. Net Loss Per Share In accordance with ASC 260 “Earnings Per Share”, basic earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus potential ordinary shares considered outstanding during the period, as long as the inclusion of such shares is not anti-dilutive. Potential ordinary shares consist of the incremental ordinary shares issuable upon the exercise of share options (using the treasury shares method), the warrants to acquire ordinary shares and the ordinary shares issuable upon vesting of the MRSUs and RSUs. The following table sets forth the computation of basic and diluted earnings per ordinary share. Quarter ended Nine months ended December 31 December 31 2015 2014 2015 2014 Numerator: Net loss $ (9,778 ) $ (42,303 ) $ (24,365 ) $ (56,638 ) Net loss available to ordinary shareholders - basic and diluted $ (9,778 ) $ (42,303 ) $ (24,365 ) $ (56,638 ) Denominator: Weighted-average shares outstanding - basic and diluted 20,398,132 15,101,441 18,284,708 14,352,476 Loss per share - basic and diluted $ (0.48 ) $ (2.80 ) $ (1.33 ) $ (3.95 ) The following table sets out the numbers of ordinary shares excluded from the above computation of earnings per share at December 31, 2015 and December 31, 2014 as their inclusion would have been anti-dilutive. December 31, 2015 December 31, 2014 Ordinary shares issuable on exercise of options to purchase ordinary shares 1,589,238 1,329,659 Restricted stock units awarded, including the multi-year performance related restricted stock units 237,695 — Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 — Ordinary shares issuable on exercise of warrants at $9.37 per share 64,000 64,000 Ordinary shares issuable on exercise of warrants at $8.80 per share — 3,955,028 Ordinary shares issuable on exercise of pre-funded warrants at $0.01 per share 850,000 850,000 2,852,458 6,198,687 |
Subsequent Events
Subsequent Events | 9 Months Ended |
Dec. 31, 2015 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 10. Subsequent Events On February 10, 2016 the Company completed a public offering of 4,444,445 of its ordinary shares at a price of $9.00 per share. The net proceeds from this offering were $36.9 million net of underwriting discounts and other offering expenses. The Company has also granted the underwriter a thirty-day option to purchase up to an additional 666,666 ordinary shares. |
Summary of Significant Accoun17
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of December, 2015 and March 31, 2015, all cash and cash equivalents comprised readily accessible cash balances except for $307 at December 31, 2015 and $314 at March 31, 2015 held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary. |
Trade Accounts Receivable | Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. |
Concentration of Credit Risks and Other Uncertainties | Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting entirely of foreign exchange contracts, are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing. The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of December 31, 2015 and at March 31, 2015. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of December 31, 2015 and March 31, 2015. This customer represented 37% and 47% of the accounts receivable balances as of December 31, 2015 and March 31, 2015, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the nine month periods ended December 31, 2015 and December 31, 2014. This customer represented 56% of total product sales for the nine month period ended December 31, 2015 and 55% for the nine month period ended December 31, 2014. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: · Level 1—Quoted prices in active markets for identical assets or liabilities. · Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. · Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 6, “Commitment and Contingencies,” for information and related disclosures regarding the Company’s fair value measurements. |
Inventory | Inventory Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of December 31, 2015 and March 31, 2015. |
Property and Equipment | Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: · Land—not depreciated. · Plant, machinery and equipment—4 to 25 years; · Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. |
Intangible Assets and Goodwill | Intangible Assets and Goodwill Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles assets—7 years The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the nine month periods ended December 31, 2015 or December 31, 2014. |
Revenue Recognition | Revenue Recognition The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. In June 2013, the Company entered into an agreement with Ortho-Clinical Diagnostics Inc. (“OCD”) to develop a range of rare antisera products. The Company had been working on this project for more than a year before the formal agreement was signed with OCD. Under the terms of the agreement, the Company is entitled to receive milestone payments of $1,400 upon the receipt of FDA approval of the rare antisera products and two further milestones of $500 each upon the updating of the CE-mark and FDA approvals to cover use of the products on OCD’s automation platform. The Company has concluded that as each of these milestones require significant levels of development work to be undertaken and there was no certainty at the start of the project that the development work would be successful, these milestones are substantive and will be accounted for under the milestone method of revenue recognition. The agreement also contains one further milestone of $650 payable upon fulfillment of $250 of cumulative orders of the rare antisera products covered by the agreement. This payment represents a royalty payment and was recognized in the quarter ended June 30, 2014 when the sales target was achieved. |
Research and Development | Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants or tax credits are available, the income concerned is included as a credit against the related expense. |
Stock-Based Compensation | Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s Condensed Consolidated Statements of Comprehensive Loss. Compensation cost related to restricted stock units with a market condition is recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided. Stock-based compensation cost for restricted stock units granted to non-employees is measured when the awards vest and the expense is recognized during the period the related services are rendered. In determining the fair value of the stock-based compensation payments in respect of share options, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures). The Company uses a barrier option pricing model to determine the grant date fair value of its multi-year performance related restricted stock unit awards. This requires the use of similar assumptions to the Black-Scholes model. |
Debt Issuance Costs | Debt Issuance Costs On September 30, 2015, the Company elected to adopt early the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. In view of the refinancing of the Company’s secured credit facility on August 3, 2015 (see note 4), the Company believes that it is preferable to adopt this presentation in the year of refinancing in order to reflect more accurately the assets of the Company and the substance of the financing arrangements. Comparative financial statements of prior years have been adjusted to apply the new presentation retrospectively. This had the effect of reducing “Prepaid expenses and other current assets” and “Other non-current assets at March 31, 2015 by $549 and $366, respectively, with a consequential reduction in “Long term debt, less current portion” of $915. There has been no impact on the comparative Statements of comprehensive loss, Statement of changes in shareholders’ deficit or Statements of cash flows. |
Intangible Assets (Tables)
Intangible Assets (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | December 31, 2015 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Ave. Remaining Useful Customer relationships $ 2,915 $ (2,915 ) $ — — Brands associated with acquired cell lines 601 (125 ) 476 31.7 years Product licenses 770 (294 ) 476 6.2 years Other intangibles 189 (189 ) — — Total $ 4,475 $ (3,523 ) $ 952 March 31, 2015 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Ave. Remaining Useful Customer relationships $ 2,923 $ (2,923 ) $ — — Brands associated with acquired cell lines 603 (115 ) 488 32.4 years Product licenses 703 (241 ) 462 6.6 years Other intangibles 190 (190 ) — — Total $ 4,419 $ (3,469 ) $ 950 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Schedule of Long-Term Debt | Long-term debt comprises: December 31, 2015 March 31, 2015 Total debt $ 30,000 $ 15,000 Less current portion — (4,500 ) Long-term debt $ 30,000 $ 10,500 Deferred debt costs, net of amortization (299 ) (428 ) Fair value of associated share warrant, net of amortization (1,012 ) (219 ) $ 28,689 $ 9,853 |
Schedule of Outstanding Debt | At December 31, 2015, the outstanding debt is repayable as follows: Within 1 year $ — Between 1 and 2 years 10,000 Between 2 and 3 years 12,000 Between 3 and 4 years 8,000 Total debt $ 30,000 |
Consolidated Balance Sheet De20
Consolidated Balance Sheet Detail (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Summary of Inventory | The following table summarizes inventory by category for the dates presented: December 31, 2015 March 31, 2015 Raw materials $ 4,137 $ 1,180 Work in progress 2,532 2,071 Finished goods 1,143 1,357 Total inventories $ 7,812 $ 4,608 |
Summary of Property and Equipment | The following table summarizes property and equipment by categories for the dates presented: December 31, 2015 March 31, 2015 Land $ 1,525 $ — Plant and Machinery 35,886 21,688 Leasehold improvements 16,350 11,412 Total property and equipment 53,761 33,100 Less: accumulated depreciation (4,817 ) (3,367 ) Total property and equipment, net $ 48,944 $ 29,733 |
Summary of Accrued Compensation and Benefits | Accrued compensation and benefits consist of the following: December 31, 2015 March 31, 2015 Salary and related benefits $ 59 $ 300 Accrued vacation 267 165 Accrued payroll taxes 551 302 Accrued incentive payments 900 1,798 Total accrued compensation and benefits $ 1,777 $ 2,565 |
Summary of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consist of the following: December 31, 2015 March 31, 2015 Accrued legal and professional fees $ 182 $ 3,758 Accrued interest 225 112 Goods received not invoiced 933 787 Accrued capital expenditure 230 972 Accrued development expenditure 1,786 2,110 Other accrued expenses 636 1,048 Total accrued expenses and other current liabilities $ 3,992 $ 8,787 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Commitments And Contingencies Disclosure [Abstract] | |
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis | The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Foreign currency forward contracts $ — $ — $ — $ — Total assets measured at fair value $ — $ — $ — $ — December 31, 2015 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts $ — $ 79 $ — $ 79 Fair value of share warrants — — — — Total liabilities measured at fair value $ — $ 79 $ — $ 79 March 31, 2015 Level 1 Level 2 Level 3 Total Assets: Foreign currency forward contracts $ — $ — $ — $ — Total assets measured at fair value $ — $ — $ — $ — March 31, 2015 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts $ 199 $ — $ — $ 199 Fair value of share warrants 31,011 — — 31,011 Total liabilities measured at fair value $ 31,210 $ — $ — $ 31,210 |
Summary of Change in Estimated Fair Value of Share Warrant Liabilities | The change in the estimated fair value of share warrant liabilities is summarized below: March 31,2015 $ 31,011 Change in fair value of ordinary share warrants (15,857 ) Exercise and expiry of warrants (15,154 ) December 31, 2015 $ — |
Ordinary Shares (Tables)
Ordinary Shares (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Ordinary Shares [Member] | |
Class Of Stock [Line Items] | |
Summary of Shares Issued and Outstanding | The Company’s issued and outstanding ordinary shares were as follows: Shares Issued and Outstanding December 31, 2015 March 31, 2015 Par value Ordinary shares 20,964,405 17,020,574 $ — Total 20,964,405 17,020,574 $ — |
7% Cumulative Redeemable Preference Shares [Member] | |
Class Of Stock [Line Items] | |
Summary of Shares Issued and Outstanding | The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share December 31, 2015 March 31, 2015 December 31, 2015 March 31, 2015 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 23.94 $ 22.76 Total 666,665 666,665 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Summary of Share Option Activity | The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2015 1,208,118 $ 5.58 103 Granted 396,427 14.86 120 Exercised (8,612 ) 4.66 — Forfeited (6,695 ) 12.08 — Outstanding — December 31, 2015 1,589,238 $ 7.87 99 Exercisable —December 31, 2015 634,466 $ 4.13 91 |
Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value | The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 20, 2015 312,300 $ 15.17 $ 15.17 $ 6.08 August 5, 2015 8,000 $ 16.70 $ 16.70 $ 6.54 September 2, 2015 25,000 $ 16.34 $ 16.34 $ 6.52 October 31, 2015 39,727 $ 11.62 $ 11.62 $ 4.76 November 4, 2015 11,400 $ 13.00 $ 13.00 $ 5.33 |
Summary of Assumptions to Share Options Issued | A summary of the assumptions applicable to the share options issued in the current financial year is as follows: May 20, 2015 August 5, 2015 September 2, 2015 October 31, 2015 November 4, 2015 Risk-free interest rate 2.29 % 2.27 % 2.18 % 2.14 % 2.23 % Expected lives (years) 3 3 3 3 3 Volatility 57.14 % 55.67 % 57.01 % 58.86 % 58.86 % Dividend yield — — — — — Grant date fair value (per share) $ 15.17 $ 16.70 $ 16.34 $ 11.62 $ 13.00 Number granted 312,300 8,000 25,000 39,727 11,400 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Earnings Per Share [Abstract] | |
Computation of Earnings Per Share Basic and Diluted | The following table sets forth the computation of basic and diluted earnings per ordinary share. Quarter ended Nine months ended December 31 December 31 2015 2014 2015 2014 Numerator: Net loss $ (9,778 ) $ (42,303 ) $ (24,365 ) $ (56,638 ) Net loss available to ordinary shareholders - basic and diluted $ (9,778 ) $ (42,303 ) $ (24,365 ) $ (56,638 ) Denominator: Weighted-average shares outstanding - basic and diluted 20,398,132 15,101,441 18,284,708 14,352,476 Loss per share - basic and diluted $ (0.48 ) $ (2.80 ) $ (1.33 ) $ (3.95 ) |
Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share | The following table sets out the numbers of ordinary shares excluded from the above computation of earnings per share at December 31, 2015 and December 31, 2014 as their inclusion would have been anti-dilutive. December 31, 2015 December 31, 2014 Ordinary shares issuable on exercise of options to purchase ordinary shares 1,589,238 1,329,659 Restricted stock units awarded, including the multi-year performance related restricted stock units 237,695 — Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 — Ordinary shares issuable on exercise of warrants at $9.37 per share 64,000 64,000 Ordinary shares issuable on exercise of warrants at $8.80 per share — 3,955,028 Ordinary shares issuable on exercise of pre-funded warrants at $0.01 per share 850,000 850,000 2,852,458 6,198,687 |
Description of Business and B25
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) | Feb. 10, 2016 | Dec. 31, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Mar. 31, 2014 |
Significant Accounting Policies [Line Items] | |||||
Accumulated deficit | $ (98,719,000) | $ (74,354,000) | |||
Cash and cash equivalents | 24,061,000 | $ 37,525,000 | $ 33,050,000 | $ 7,192,000 | |
Covenants with lenders to maintain minimum cash holdings | $ 10,000,000 | ||||
Ordinary Shares [Member] | Subsequent Event | |||||
Significant Accounting Policies [Line Items] | |||||
Underwritten equity offering | $ 36,900,000 |
Summary of Significant Accoun26
Summary of Significant Accounting Policies - Additional Information (Detail) | Dec. 31, 2015USD ($)Customer | Mar. 31, 2015USD ($)Customer | Jun. 30, 2013USD ($)Payments | Dec. 31, 2015USD ($)Customer | Dec. 31, 2014USD ($)Customer |
Significant Accounting Policies [Line Items] | |||||
Restricted cash | $ 307,000 | $ 314,000 | $ 307,000 | ||
Number of customer represent 10% or more of accounts receivable | Customer | 1 | 1 | 1 | ||
Number of customer represent 10% or more of product sales | Customer | 1 | 1 | |||
Stock-based compensation cost included in inventory | $ 0 | $ 0 | $ 0 | ||
Impairment losses | $ 0 | $ 0 | |||
Milestone amount receivable upon fulfillment of achievement target order | $ 650,000 | ||||
Milestone cumulative orders target | 250,000 | ||||
Reduction in prepaid expenses and other current assets | 549,000 | ||||
Reduction in other non-current assets | 366,000 | ||||
Reduction in long term debt, net | $ 915,000 | ||||
Customer Relationships [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets amortization over estimated useful life | 5 years | ||||
Brands Associated with Acquired Cell Lines [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets amortization over estimated useful life | 40 years | ||||
Product Licenses [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets amortization over estimated useful life | 10 years | ||||
Other Intangibles Assets [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets amortization over estimated useful life | 7 years | ||||
FDA [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Milestone amount receivable upon fulfillment of achievement | 1,400,000 | ||||
CE-Marks & FDA [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Milestone amount receivable upon fulfillment of achievement | $ 500,000 | ||||
Number of milestone payments | Payments | 2 | ||||
Minimum [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Plant, machinery and equipment useful life | 4 years | ||||
Maximum [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Plant, machinery and equipment useful life | 25 years | ||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Concentration risk percentage | 37.00% | 47.00% | |||
Customer Concentration Risk [Member] | Sales [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Concentration risk percentage | 56.00% | 55.00% |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Dec. 31, 2015 | Mar. 31, 2015 | |
Finite Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 4,475 | $ 4,419 |
Accumulated Amortization | (3,523) | (3,469) |
Net Carrying Amount | 952 | 950 |
Customer Relationships [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 2,915 | 2,923 |
Accumulated Amortization | (2,915) | (2,923) |
Brands Associated with Acquired Cell Lines [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 601 | 603 |
Accumulated Amortization | (125) | (115) |
Net Carrying Amount | $ 476 | $ 488 |
Weighted-Average Remaining Useful Life | 31 years 8 months 12 days | 32 years 4 months 24 days |
Product Licenses [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 770 | $ 703 |
Accumulated Amortization | (294) | (241) |
Net Carrying Amount | $ 476 | $ 462 |
Weighted-Average Remaining Useful Life | 6 years 1 month 6 days | 6 years 7 months 6 days |
Other Intangibles Assets [Member] | ||
Finite Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 189 | $ 190 |
Accumulated Amortization | $ (189) | $ (190) |
Debt - Schedule of Long-Term De
Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Debt Disclosure [Abstract] | ||
Total debt | $ 30,000 | $ 15,000 |
Less current portion | (4,500) | |
Long-term debt | 30,000 | 10,500 |
Deferred debt costs, net of amortization | (299) | (428) |
Fair value of associated share warrant, net of amortization | (1,012) | (219) |
Long-term debt, less current portion | $ 28,689 | $ 9,853 |
Debt - Additional Information (
Debt - Additional Information (Detail) - USD ($) $ in Thousands | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Aug. 03, 2015 | |
Debt Instrument [Line Items] | |||
Deferred debt fees expensed | $ 1,250 | $ 587 | |
MidCap Financial Trust [Member] | Secured Credit Facility Agreement [Member] | |||
Debt Instrument [Line Items] | |||
Drew down with new secured bank facility agreement | $ 30,000 | ||
Facility repayable period | 4 years | ||
Margin over LIBOR rate | 6.70% | ||
Long-term debt repayable terms | The facility is repayable over a four year period with no repayments until March 1, 2017 when the first of 30 equal monthly repayments is due. If the Company achieves CE Mark approvals for the MosaiQTM instrument and blood grouping consumable, the facility is repayable over a four year period with no repayments until September 1, 2017 when the first of 24 equal monthly repayments is due. | ||
Facility bears interest | LIBOR plus 6.7% | ||
LIBOR rate applicable terms | LIBOR rate applicable is the higher of the actual market rate from time to time or 2.0%. | ||
MidCap Financial Trust [Member] | Secured Credit Facility Agreement [Member] | Other Expense [Member] | |||
Debt Instrument [Line Items] | |||
Deferred debt fees expensed | $ 600 |
Debt - Schedule of Outstanding
Debt - Schedule of Outstanding Debt (Detail) $ in Thousands | Dec. 31, 2015USD ($) |
Long-term Debt, Rolling Maturity [Abstract] | |
Between 1 and 2 years | $ 10,000 |
Between 2 and 3 years | 12,000 |
Between 3 and 4 years | 8,000 |
Total debt | $ 30,000 |
Consolidated Balance Sheet De31
Consolidated Balance Sheet Detail - Summary of Inventory (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 4,137 | $ 1,180 |
Work in progress | 2,532 | 2,071 |
Finished goods | 1,143 | 1,357 |
Total inventories | $ 7,812 | $ 4,608 |
Consolidated Balance Sheet De32
Consolidated Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 53,761 | $ 33,100 |
Less: accumulated depreciation | (4,817) | (3,367) |
Total property and equipment, net | 48,944 | 29,733 |
Land [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 1,525 | |
Plant and Machinery [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 35,886 | 21,688 |
Leasehold Improvements [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 16,350 | $ 11,412 |
Consolidated Balance Sheet De33
Consolidated Balance Sheet Detail - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Property Plant And Equipment [Abstract] | ||||
Depreciation expenses | $ 643 | $ 316 | $ 1,510 | $ 873 |
Consolidated Balance Sheet De34
Consolidated Balance Sheet Detail - Summary of Accrued Compensation and Benefits (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Compensation Related Costs [Abstract] | ||
Salary and related benefits | $ 59 | $ 300 |
Accrued vacation | 267 | 165 |
Accrued payroll taxes | 551 | 302 |
Accrued incentive payments | 900 | 1,798 |
Total accrued compensation and benefits | $ 1,777 | $ 2,565 |
Consolidated Balance Sheet De35
Consolidated Balance Sheet Detail - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Payables And Accruals [Abstract] | ||
Accrued legal and professional fees | $ 182 | $ 3,758 |
Accrued interest | 225 | 112 |
Goods received not invoiced | 933 | 787 |
Accrued capital expenditure | 230 | 972 |
Accrued development expenditure | 1,786 | 2,110 |
Other accrued expenses | 636 | 1,048 |
Total accrued expenses and other current liabilities | $ 3,992 | $ 8,787 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) $ / shares in Units, £ in Thousands | Oct. 26, 2015shares | Dec. 31, 2008GBP (£) | Dec. 31, 2015GBP (£) | Dec. 31, 2015USD ($)Contracts$ / £ | Mar. 31, 2015USD ($) | Apr. 30, 2014$ / sharesshares |
Commitments And Contingencies Disclosure [Abstract] | ||||||
Research and development grant funding from Scottish Enterprise | £ | £ 1,791 | |||||
Claims from grant | £ | £ 1,790 | |||||
Number of forward exchange contracts | Contracts | 12 | |||||
Forward exchange contracts sold | $ | $ 500,000 | |||||
Forward exchange contract US Dollars to pound sterling | $ / £ | 1.50 | |||||
Issued warrants to acquire common shares | 5,000,000 | |||||
Ordinary share acquired for each unit of warrant | 0.8 | |||||
Exercise of warrants per share | $ / shares | $ 8.80 | |||||
Number of warrants exercised | 4,981,052 | |||||
Number of warrants expired | 18,948 | |||||
Financial liability of outstanding warrants | $ | $ 0 | $ 31,011,000 |
Commitments and Contingencies37
Commitments and Contingencies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) | Dec. 31, 2015 | Mar. 31, 2015 |
Liabilities: | ||
Total liabilities measured at fair value | $ 0 | $ 31,011,000 |
Recurring [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 79,000 | 31,210,000 |
Recurring [Member] | Foreign currency forward contracts [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 79,000 | 199,000 |
Recurring [Member] | Fair value of share warrants [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 31,011,000 | |
Recurring [Member] | Level 1 [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 31,210,000 | |
Recurring [Member] | Level 1 [Member] | Foreign currency forward contracts [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 199,000 | |
Recurring [Member] | Level 1 [Member] | Fair value of share warrants [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | $ 31,011,000 | |
Recurring [Member] | Level 2 [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | 79,000 | |
Recurring [Member] | Level 2 [Member] | Foreign currency forward contracts [Member] | ||
Liabilities: | ||
Total liabilities measured at fair value | $ 79,000 |
Commitments and Contingencies38
Commitments and Contingencies - Summary of Change in Estimated Fair Value of Share Warrant Liabilities (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Commitments And Contingencies Disclosure [Abstract] | ||||
Warrant at fair value, Beginning balance | $ 31,011 | |||
Change in fair value of ordinary share warrants | $ (3,830) | $ 34,565 | (15,857) | $ 33,581 |
Exercise and expiry of warrants | $ (15,154) |
Ordinary Shares - Summary of Sh
Ordinary Shares - Summary of Shares Issued and Outstanding (Detail) - $ / shares | Dec. 31, 2015 | Mar. 31, 2015 |
Class Of Stock [Line Items] | ||
Common stock, shares issued | 20,964,405 | 17,020,574 |
Common stock, shares outstanding | 17,020,574 | |
Common stock, par value | ||
Preferred stock, shares issued | 666,665 | 666,665 |
Preferred stock, shares outstanding | 666,665 | 666,665 |
Ordinary Shares [Member] | ||
Class Of Stock [Line Items] | ||
Common stock, shares issued | 20,964,405 | 17,020,574 |
Common stock, shares outstanding | 20,964,405 | 17,020,574 |
Common stock, par value | ||
7% Cumulative Redeemable Preference Shares [Member] | ||
Class Of Stock [Line Items] | ||
Preferred stock, shares issued | 666,665 | 666,665 |
Preferred stock, shares outstanding | 666,665 | 666,665 |
Liquidation amount per share | $ 23.94 | $ 22.76 |
Ordinary Shares - Summary of 40
Ordinary Shares - Summary of Shares Issued and Outstanding (Parenthetical) (Detail) | 9 Months Ended |
Dec. 31, 2015 | |
7% Cumulative Redeemable Preference Shares [Member] | |
Class Of Stock [Line Items] | |
Dividend percentage | 7.00% |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Nov. 04, 2015 | Oct. 31, 2015 | Sep. 04, 2015 | Sep. 02, 2015 | Aug. 05, 2015 | May. 20, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Dec. 31, 2015 | Dec. 31, 2014 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Share-based compensation expense | $ 566 | $ 305 | $ 1,380 | $ 814 | |||||||
Risk-free interest rate, Description | Risk-Free Interest Rate. The risk-free interest rate is based on the US Treasury 10-year bond yield in effect at the time of grant. | ||||||||||
Number of restricted stock units awarded | 12,500 | ||||||||||
Grant date fair value (per share) | $ 13 | $ 11.62 | $ 16.34 | $ 16.70 | $ 15.17 | ||||||
Multi Year Performance Based Restricted Stock Units | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Number of restricted stock units awarded | 137,000 | ||||||||||
Award vesting description | if the volume weighted average price of the Company’s ordinary shares exceeds $60 for a continuous twenty day period between April 1, 2018 and December 31, 2018 | ||||||||||
Grant date fair value (per share) | $ 6.09 | ||||||||||
Restricted Stock Units (RSUs) | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Vesting period | 3 years | 2 years | 2 years | 2 years | 2 years | 4 years | |||||
Number of restricted stock units awarded | 8,000 | 10,328 | 9,867 | 25,000 | 10,000 | 50,000 | |||||
Number of RSU's vested during period | 12,500 | ||||||||||
Number of RSU's outstanding | 37,500 | 37,500 | |||||||||
Employee Stock Option [Member] | Minimum [Member] | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Vesting period | 1 year | ||||||||||
Employee Stock Option [Member] | Maximum [Member] | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Vesting period | 3 years | ||||||||||
Ordinary Shares [Member] | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Company's closing share price | $ 16 | $ 16 | |||||||||
Ordinary Shares [Member] | Minimum [Member] | |||||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||||
Weighted average price of shares | $ 60 |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of Share Option Activity (Detail) - $ / shares | Nov. 04, 2015 | Oct. 31, 2015 | Sep. 02, 2015 | Aug. 05, 2015 | May. 20, 2015 | Dec. 31, 2015 | Mar. 31, 2015 |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||||||
Number of Share Options Outstanding, Beginning Balance | 1,208,118 | ||||||
Number of Share Options Outstanding, Granted | 11,400 | 39,727 | 25,000 | 8,000 | 312,300 | 396,427 | |
Number of Share Options Outstanding, Exercised | (8,612) | ||||||
Number of Share Options Outstanding, Forfeited | (6,695) | ||||||
Number of Share Options Outstanding, Ending Balance | 1,589,238 | 1,208,118 | |||||
Number of Share Options Outstanding, Exercisable | 634,466 | ||||||
Weighted-Average Exercise Price, Beginning Balance | $ 5.58 | ||||||
Weighted-Average Exercise Price, Granted | 14.86 | ||||||
Weighted-Average Exercise Price, Exercised | 4.66 | ||||||
Weighted-Average Exercise Price, Forfeited | 12.08 | ||||||
Weighted-Average Exercise Price, Ending Balance | 7.87 | $ 5.58 | |||||
Weighted-Average Exercise Price, Exercisable | $ 4.13 | ||||||
Weighted-Average Remaining Contractual Life, Outstanding | 99 months | 103 months | |||||
Weighted-Average Remaining Contractual Life, Granted | 120 months | ||||||
Weighted-Average Remaining Contractual Life, Exercisable | 91 months |
Share-Based Compensation - Su43
Share-Based Compensation - Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value (Detail) - $ / shares | Nov. 04, 2015 | Oct. 31, 2015 | Sep. 02, 2015 | Aug. 05, 2015 | May. 20, 2015 | Dec. 31, 2015 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Number of Options Granted | 11,400 | 39,727 | 25,000 | 8,000 | 312,300 | 396,427 |
Exercise Price | $ 14.86 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | $ 13 | $ 11.62 | $ 16.34 | $ 16.70 | $ 15.17 | |
May 20, 2015 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Grant Date | May 20, 2015 | |||||
Number of Options Granted | 312,300 | |||||
Exercise Price | $ 15.17 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | 15.17 | |||||
Per Share Intrinsic Value of Options | $ 6.08 | |||||
August 5, 2015 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Grant Date | Aug. 5, 2015 | |||||
Number of Options Granted | 8,000 | |||||
Exercise Price | $ 16.70 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | 16.70 | |||||
Per Share Intrinsic Value of Options | $ 6.54 | |||||
September 2, 2015 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Grant Date | Sep. 2, 2015 | |||||
Number of Options Granted | 25,000 | |||||
Exercise Price | $ 16.34 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | 16.34 | |||||
Per Share Intrinsic Value of Options | $ 6.52 | |||||
October 31, 2015 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Grant Date | Oct. 31, 2015 | |||||
Number of Options Granted | 39,727 | |||||
Exercise Price | $ 11.62 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | 11.62 | |||||
Per Share Intrinsic Value of Options | $ 4.76 | |||||
November 4, 2015 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Grant Date | Nov. 4, 2015 | |||||
Number of Options Granted | 11,400 | |||||
Exercise Price | $ 13 | |||||
Ordinary Shares Fair Value Per Share at Grant Date | 13 | |||||
Per Share Intrinsic Value of Options | $ 5.33 |
Share-Based Compensation - Su44
Share-Based Compensation - Summary of Assumptions to Share Options Issued (Detail) - $ / shares | Nov. 04, 2015 | Oct. 31, 2015 | Sep. 02, 2015 | Aug. 05, 2015 | May. 20, 2015 | Dec. 31, 2015 |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ||||||
Risk-free interest rate | 2.23% | 2.14% | 2.18% | 2.27% | 2.29% | |
Expected lives (years) | 3 years | 3 years | 3 years | 3 years | 3 years | |
Volatility | 58.86% | 58.86% | 57.01% | 55.67% | 57.14% | |
Grant date fair value (per share) | $ 13 | $ 11.62 | $ 16.34 | $ 16.70 | $ 15.17 | |
Number of Share Options Outstanding, Granted | 11,400 | 39,727 | 25,000 | 8,000 | 312,300 | 396,427 |
Net Loss Per Share - Computatio
Net Loss Per Share - Computation of Earnings Per Share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Numerator: | ||||
Net loss | $ (9,778) | $ (42,303) | $ (24,365) | $ (56,638) |
Net loss available to ordinary shareholders - basic and diluted | $ (9,778) | $ (42,303) | $ (24,365) | $ (56,638) |
Denominator: | ||||
Weighted-average shares outstanding - basic and diluted | 20,398,132 | 15,101,441 | 18,284,708 | 14,352,476 |
Loss per share - basic and diluted | $ (0.48) | $ (2.80) | $ (1.33) | $ (3.95) |
Net Loss Per Share - Summary of
Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) - shares | Dec. 31, 2015 | Dec. 31, 2014 |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 2,852,458 | 6,198,687 |
Exercise Of Options To Purchase Ordinary Shares | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 1,589,238 | 1,329,659 |
Restricted Stock Units Awarded, Including Multi-Year Performance | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 237,695 | |
Exercise Of Warrants At $16.14 Per Share | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 111,525 | |
Exercise Of Warrants At $9.37 Per Share | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 64,000 | 64,000 |
Exercise Of Warrants At $8.80 Per Share | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 3,955,028 | |
Exercise Of Pre-Funded Warrants At $0.01 Per Share | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Ordinary shares issuable excluded from computation of earnings per share | 850,000 | 850,000 |
Net Loss Per Share - Summary 47
Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) (Parenthetical) - $ / shares | Dec. 31, 2015 | Dec. 31, 2014 | Apr. 30, 2014 |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |||
Exercise of warrants per share | $ 8.80 | ||
Exercise Of Warrants At $16.14 Per Share | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |||
Exercise of warrants per share | $ 16.14 | ||
Exercise Of Warrants At $9.37 Per Share | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |||
Exercise of warrants per share | 9.37 | $ 9.37 | |
Exercise Of Warrants At $8.80 Per Share | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |||
Exercise of warrants per share | 8.80 | ||
Exercise Of Pre-Funded Warrants At $0.01 Per Share | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |||
Exercise of warrants per share | $ 0.01 | $ 0.01 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions | Feb. 10, 2016 | Dec. 31, 2015 |
Ordinary Shares [Member] | ||
Subsequent Event [Line Items] | ||
Underwritten public offering, per shares | $ 16 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Number of days option granted to underwriters | 30 days | |
Subsequent Event | Ordinary Shares [Member] | ||
Subsequent Event [Line Items] | ||
Underwritten equity offering | $ 36.9 | |
Underwritten public offering, shares | 4,444,445 | |
Underwritten public offering, per shares | $ 9 | |
Additional number of shares available for grant | 666,666 |